- Report
- October 2024
- 197 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- October 2024
- 189 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- February 2025
- 200 Pages
Global
From €4288EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4288EUR$4,490USD£3,586GBP
- Report
- November 2024
- 150 Pages
Global
From €4632EUR$4,850USD£3,873GBP
- Report
- September 2024
- 150 Pages
Global
From €4632EUR$4,850USD£3,873GBP
- Report
- November 2024
- 110 Pages
United States
From €5682EUR$5,950USD£4,752GBP
- Report
- October 2023
- 85 Pages
United States
From €4632EUR$4,850USD£3,873GBP
- Report
- April 2023
- 147 Pages
Global
From €4726EUR$4,949USD£3,953GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4727EUR$4,950USD£3,953GBP
- Report
- February 2024
- 120 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- August 2022
- 111 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- October 2023
- 145 Pages
Global
From €3008EUR$3,150USD£2,516GBP
- Report
- January 2024
- 138 Pages
United States
€3629EUR$3,800USD£3,035GBP
- Report
- August 2024
- 81 Pages
Global
From €3500EUR$3,926USD£3,029GBP

Ankylosing Spondylitis (AS) is a chronic, inflammatory disorder of the spine and sacroiliac joints. It is classified as a type of spondyloarthritis, a group of diseases that affect the spine and other joints. AS is an autoimmune disorder, meaning that the body's immune system mistakenly attacks healthy tissue. Symptoms of AS include pain and stiffness in the lower back and hips, fatigue, and reduced mobility. Treatment options include physical therapy, exercise, and medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and biologic drugs.
The Ankylosing Spondylitis market is a subset of the Allergy and Immunology market. It is a growing market, driven by the increasing prevalence of AS and the development of new treatments. The market is highly competitive, with a number of companies offering treatments for AS.
Some companies in the Ankylosing Spondylitis market include AbbVie, Amgen, Pfizer, and UCB. Show Less Read more